Search

Search Results

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277582

  PDF: 1760

  HTML: 3843

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  3054

  PDF: 1183

  HTML: 3457

• Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review

  Domenico Santorsola, Elisabetta Abruzzese

  e2015020

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.020

  1970

  PDF: 1194

  HTML: 1616

• Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature

  Ekaterina Chelysheva, Sergey Aleshin, Evgenia Polushkina, Roman Shmakov, Igor Shokhin, Ghermes Chilov, Anna Turkina

  e2018027

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.027

  3060

  PDF: 965

  HTML: 338

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3243

  PDF: 1433

  HTML: 3985

• TYROSINE KINASE INHIBITORS AND PREGNANCY

  Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti

  e2014028

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.028

  3452

  PDF: 1586

  HTML: 2663

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  3452

  PDF: 1538

  HTML: 561

• TYROSINE KINASE INHIBITORS AND INTERFERON

  Maria Dimou, Panagiotis Panagiotidis

  e2014006

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.006

  2810

  PDF: 1398

  HTML: 3040

  Cover Letter: 187

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  1998

  PDF: 1476

  HTML: 260

• IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?

  Federica Sorà, Patrizia Chiusolo, Francesco autore, Sabrina Giammarco, luca laurenti, elisabetta metafuni, idanna innocenti, eugenio galli, andrea bacigalupo, simona sica

  e2021062

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.062

  1175

  PDF: 442

  HTML: 142

• CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY

  Maria Ilaria Del Principe, Luca Maurillo, Francesco Buccisano, Giuseppe Sconocchia, Mariagiovanna Cefalo, Giovanna De Santis, Ambra Di Veroli, Concetta Ditto, Daniela Nasso, Massimiliano Postorino, Marco Refrigeri, Cristina Attrotto, Giovanni Del Poeta, Sergio Amadori, Adriano Venditti

  e2014075

  2014-11-01

  https://doi.org/10.4084/mjhid.2014.075

  3981

  PDF: 1900

  HTML: 5199

  Table 1: 173

• Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

  Nathalia Sena de Oliveira Silva, Gislaine Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, Katia Borgia Barbosa Pagnano

  e2026001

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.001

  605

  PDF: 399

  Html: 69

• MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

  Ibrahim C. Haznedaroglu

  e2014009

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.009

  3850

  PDF: 1454

  HTML: 9175

  Untitled: 260

  Untitled: 168

  Untitled: 152

  Untitled: 147

  Untitled: 164

  Untitled: 321

• SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

  Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini

  e2021046

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.046

  1345

  PDF: 612

  HTML: 230

• A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fabrizio Pane

  e2014010

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.010

  3180

  PDF: 1305

  HTML: 4108

• Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

  Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena

  e2016016

  2016-02-20

  https://doi.org/10.4084/mjhid.2016.016

  2876

  PDF: 669

  HTML: 1920

  figure 1: 154

  figure 2: 168

• DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia

  Buket Altinok Gunes, Yalda Hekmatshoar, Tulin Ozkan, Sureyya Bozkurt, O.Sena Aydos, Yahya Buyukasik, Elifcan Aladag, Asuman Sunguroglu

  e2023008

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.008

  1253

  PDF: 1149

  HTML: 428

• IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

  Tomasz Sacha

  e2014007

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.007

  4590

  PDF: 2755

  HTML: 2253

• Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review

  Toshifumi Takahashi

  e2020005

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.005

  1714

  PDF: 1152

  HTML: 270

• Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption

  Judit Demeter, Julia Weisinger, Zsolt Nagy

  e2021022

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.022

  1357

  PDF: 456

  HTML: 211

• Fecal microbiota transplantation as a salvage therapy for concomitant resistant digestive graft versus host disease and cryptosporidiosis in a patient post hematopoietic stem cell transplant : about a case

  Thomas Finotto, Carole Chevenet, Amandine Fayard

  e2025035

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.035

  992

  PDF: 776

  HTML: 62

• SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19

  Elisabetta Abruzzese, Luigia Luciano, Francesco D'Agostino, Malgorzata Monika Trawinska, Fabrizio Pane, Paolo de Fabritiis

  e2020031

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.031

  3196

  PDF: 1490

  HTML: 401

• FACTORS INFLUENCING ADHERENCE TO IMATINIB IN INDIAN CHRONIC MYELOID LEUKEMIA PATIENTS: A CROSS-SECTIONAL STUDY

  Jyotsna Kapoor, Narendra Agrawal, Rayaz Ahmad, Sanjeev Kumar Sharma, Anshul Gupta, Dinesh Bhurani

  e2015013

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.013

  1918

  PDF: 1048

  HTML: 1773

• TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION

  Elisabetta Abruzzese

  e2019025

  2019-04-26

  https://doi.org/10.4084/mjhid.2019.025

  1919

  PDF: 1040

  HTML: 170

• CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY

  Lodovico Balducci

  e2014037

  2014-05-31

  https://doi.org/10.4084/mjhid.2014.037

  2846

  PDF: 1074

  HTML: 3021

• Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a real world setting

  Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà

  e2026013

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.013

  531

  PDF: 409

  Html: 69

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  2772

  PDF: 699

  HTML: 892